WebThe acquisition deal proposed that Concentra would acquire Jounce for $1.85 per share, along with a non-tradeable contingent value right. The offer represented a premium of 75% against Jounce’s closing price on March 14, and even after the recent rise, it still represents a premium of about $0.03 per share since it closed at $1.82. Web15 hours ago · Zacks News for CYCN Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates ... 04/03/23-6:35AM EST Thefly.com Biotech Alert: Searches spiking for these stocks today 03/29/23 ...
Breaking News: CYCN latest news. - The Fly
WebCyclerion Therapeutics, Inc. (CYCN) Latest Stock News & Headlines - Yahoo Finance Watchlists My Portfolio Crypto Yahoo Finance Plus Videos S&P 500 Dow 30 +132.28(+0.41%) Nasdaq 11,823.96... WebJun 4, 2024 · Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion is advancing novel, first-in-class, CNS-penetrant,... how to spawn primadon
Cyclerion Therapeutics Enters into Exclusive Negotiation …
WebSep 24, 2024 · Insights from these analyses are expected to accelerate and support further clinical development of CY6463. CY6463 is an oral, first-in-class, central nervous system … WebSep 24, 2024 · The Fly team scours all sources of company news, from mainstream to cutting edge,then filters out the noise to deliver shortform stories consisting of only market moving content. Breaking News: CYCN latest news. - The Fly We use cookies to improve user experience, and analyze website traffic. WebMar 27, 2024 · Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases. Cyclerion’s portfolio includes novel … rcmp indigenous policing